Evenity
(Romosozumab SQ)
Provider Summary
Primary Uses
Treatment of osteoporosis in postmenopausal women at high risk for fracture per criteria.
Mechanism of action
Sclerostin inhibitor increases bone formation and decreases bone resorption.
Pre-treatment / baseline requirements
Baseline calcium and vitamin D; correct hypocalcemia; assess cardiovascular risk history; dental evaluation for ONJ risk in appropriate patients.
Common side effects
Arthralgia, headache, injection site reactions.
Serious adverse effects / key risks
Boxed warning: increased risk of MI, stroke, and cardiovascular death; hypocalcemia; osteonecrosis of the jaw; atypical femur fracture.
Referral requirements
Standard infusion referral form + drug-specific checklist
Duration note
Therapy is limited to 12 monthly doses (12 months). Patients are typically transitioned to an antiresorptive agent afterward to maintain gains.
Patient & Caregiver Education
What it treats
Treatment of osteoporosis in postmenopausal women at high risk for fracture
How it works
Blocks sclerostin to build bone and reduce bone loss.
Before treatment
Tell your clinician if you have an active infection/fever, are pregnant/planning pregnancy, or have major heart/nerve problems. Depending on the medication, you may need labs or screening tests (e.g., TB/hepatitis) and a vaccine review.
Common side effects
Arthralgia, headache, injection site reactions.
Get urgent help for
Boxed warning: increased risk of MI, stroke, and cardiovascular death; hypocalcemia; osteonecrosis of the jaw; atypical femur fracture.
On treatment day
Plan to stay for monitoring. If you feel dizzy, drowsy, or unwell afterward, do not drive and follow your clinician’s instructions.